



Support • Progress • Promote

A review of the **IBMS 2022– 2025 strategy**

**The difference we made to members
and biomedical science**

Published in January 2026

Contents

Our work	3
Introduction from our Chief Executive	4
Key highlights from the 2022-2025 strategy	5
Our 2022-2025 strategy	6-7
Our achievements	8-13
Our strategy for 2026-2029	14-15



Our work

We're the professional body for scientists, support staff and students working in biomedical science. For over 100 years, we've made sure our members operate to the highest professional standards.

From students to advanced practitioners with decades of experience, our members work at all levels in biomedical science. Most work in healthcare, but some are based in universities, veterinary laboratories and government agencies. We also have diagnostic companies as members, which helps us to keep up to date with the latest developments in technology and advances in scientific techniques.

Find out more about [what we do](#), and how we support our members and the profession.

 [Read our mission, values and values](#)



“

Whether you want to be a manager or a training officer, the IBMS offers different courses to help members progress in biomedical science. The IBMS is the voice of the profession and offers a support system for the careers of biomedical scientists.”

Zonya Jeffery, a Senior Biomedical Scientist and Training Manager at the Manchester University NHS Foundation Trust and IBMS Council Member

Introduction from our Chief Executive



I'm proud of all the work we achieved during the last strategy period. The IBMS is a very different organisation to the one I took over in 2021. We've grown in every facet that we need to. We've brought our qualifications into the modern age, changed our advocacy work dramatically, raised our profile and helped grow the number of biomedical scientists taking on consultant roles.

For me, some of the highlights of the previous strategy period were:

- ◆ increasing the number of people that we trained as verifiers
- ◆ launching digital portfolios for all of our core qualifications to make them more accessible to members
- ◆ our 'Become a biomedical scientist' campaign reaching over 1 million views on social media
- ◆ recruiting new digital and learning staff into the team to support changes in the way people learn.

Our advocacy work has changed a lot during this strategy period. We've published white papers and developed strong links with the government and policy leads in the NHS. Organisations like Roche Diagnostics, AstraZeneca and Microsoft for Healthcare approached us to work on papers with them. People are now seeing us as an organisation to be associated with. This is a really positive step for the IBMS.

Serving parliamentarians attended our last few Congresses, which has never happened before. Members of the UK government are attending and speaking at the event, which shows how the profile of the IBMS has increased.

THE FOCUS OF OUR 2026-2029 STRATEGY

Our new strategy builds on the success of the 2022-2025 one. We made significant progress and delivered strong outcomes in the last strategy period and will now take it to the next level.

Our ambition for the 2026-2029 strategy is to position the IBMS as the recognised leading professional body for biomedical science, advising on pathology, both in the UK and internationally. We want members and policymakers to see the IBMS as an organisation they need to engage with.

SUPPORTING OUR MEMBERS

We want to meet the needs of current and future members, from students to registered biomedical scientists. This includes providing high-quality CPD and qualifications so members can progress their careers in biomedical science.

None of this work is possible without our volunteers. This includes Council members, our President, volunteers who help set exams and people who verify them, and those sitting on Specialist Advisory Panels. The previous strategy was delivered in support of the membership, by the membership, and our new one recognises that everyone's got a part to play in delivering it.

David Wells, IBMS Chief Executive

Key highlights from the 2022–2025 strategy

We are proud to share some of the highlights of our work between 2022 and 2025.

- We increased the number of verifiers by **33%** between 2022 and 2025, bringing the total to **927**. This is helping us to assess more registration training and specialist qualifications for biomedical scientists.
- Our 'Become a biomedical scientist' campaign reached over **1 million** people on social media between 2022 and 2025 and received three membership sector awards. The campaign raised awareness of biomedical science careers and guided aspiring professionals into the field.
- To support trainers and training officers in the laboratory, we started hosting **regular webinar sessions** on our Support Forum in 2023. These are supporting experienced and new training officers to share ideas and solve problems together.
- Our collaboration with NHS England and Health Education England means that learners across England received nearly **£1 million** worth of funding to complete IBMS qualifications.
- In 2023, we launched an **Advanced Specialist Diploma in Bowel Screening Histopathology Reporting** and one in **Cervical Histopathology Reporting**. Biomedical scientists who take on these roles after qualifying will help to reduce waiting times for cancer diagnosis.
- We published and promoted our bold **Long Term Biomedical Scientist Workforce Plan**. It sets out the support and opportunities we will provide to biomedical scientists to keep pace with the rapidly changing profession and patients' growing needs. The plan outlines our commitment to making sure biomedical scientists will be a key part of successfully delivering on the NHS Long Term Workforce Plan.
- The presence of biomedical scientists in the bowel cancer patient pathway benefits the NHS by an estimated **£115 million to £571 million a year**. That was one of the findings of an independent report, from economics consultancy Oxera, about the impact of biomedical scientists on the bowel cancer patient pathway. It demonstrates the need for wider recognition from the UK government of the biomedical scientist workforce.



Our 2022–2025 strategy

Our 2022–2025 strategy was split into two parts with a series of aims.

PART ONE: WE WILL BUILD ON OUR EXPERIENCE AND EXPERTISE

The long-term future of the IBMS will depend on the future of the profession. Biomedical science needs to keep pace with technology and advances in healthcare. To help achieve this, we must make sure that the IBMS remains relevant and fit for purpose for members.



◆ AIM 1

Support more access to the Health and Care Professions Council (HCPC) registration through better uptake of entry routes to become a biomedical scientist. Provide greater clarity of the routes to entry and encourage more students to choose the most efficient route to HCPC registration. Champion the role of trainers and training officers in the laboratory.

◆ AIM 2

Progress our current members' knowledge, experience and their careers through better and more relevant training and qualifications, using our existing structures but allowing a more agile application. Create a more inclusive approach to support greater diversity, championing our members' values such as sustainability and clear professional standards.

◆ AIM 3

Promote our highest qualifications, widening the disciplines that these are available in and increasing the number of members accessing them.

PART TWO: WE WILL BUILD AND DEVELOP OUR FUTURE

This part of the strategy looked at how we would use our reserves between 2022 and 2025 to support the IBMS, our work and our members.

◆ AIM 1


Promote our profile post-pandemic, to develop a policy and engagement capability at government level for each of the four nations.

◆ AIM 2

Progress the numbers and range of members that the IBMS attracts, within the UK and globally.

◆ AIM 3

Support the understanding of the benefit the profession and biomedical science delivers to society.



7



WHAT WE DO FOR OUR MEMBERS

Our strategic aims were split into three areas of work that focus on what we do for members. These were:

◆ SUPPORT

We provide members with professional standards and support to make sure they practise safely and deliver high-quality work.

◆ PROGRESS

We provide members with access to training, qualifications and knowledge to progress their careers and stay relevant as the profession changes.

◆ PROMOTE

We provide members with a strong, respected and progressive voice to promote the profession at all levels.



“

Being an IBMS member has given me the confidence to do the job I do. It's been an important part of my professional life and helped me to develop. I wouldn't have done half the things I've done if it hadn't been for the support of the IBMS. The more members get involved with their professional membership body, the more they get out of it. The IBMS is good at spotting when you have the aptitude and skills to do something. If someone's asked you to do something, and you're not sure if you can do it, say to yourself: 'They might have seen something in me that I haven't seen.'”

Dr Sarah Pitt, President of the IBMS for 2026 to 2027

Our achievements

In this section, we look at the difference we made to members and biomedical science during the course of the 2022–2025 strategy. Here, we look at some of our biggest achievements over the last four years.

PART ONE OF THE STRATEGY:

The long-term future of the IBMS will depend on the future of the profession. Biomedical science needs to keep pace with technology and advances in healthcare. To help achieve this, we must make sure that the IBMS remains relevant and fit for purpose for members.

WE SUPPORTED ACCESS TO HCPC REGISTRATION

- ◆ The number of verifiers increased by **33%** between 2022 and 2025, bringing the total to **927**. This helps us to assess more registration training and specialist qualifications for biomedical scientists. We recruited and trained more verifiers by holding extra ‘Train the Trainer’ events on the updated Registration Training Portfolio and Specialist Portfolios.



- ◆ We launched **digital versions of the IBMS Registration Training Portfolio** on OneFile. This is allowing training officers to create tailored training and assessments for candidates and it simplifies the administration of the Registration Training Portfolio.
- ◆ Using a combination of virtual reality and targeted video, the ‘Become a biomedical scientist’ campaign reached over **1 million people** on social media between 2022 and 2025. The campaign also won three awards in 2024 at the Association Excellence Awards and Memcom Excellence Awards.
- ◆ To highlight the different ways people can become a biomedical scientist and the importance of taking an IBMS Accredited degree, we designed and shared a **new ‘IBMS Accredited’ logo** with all accredited universities to use on their websites and social media channels.



Being an IBMS portfolio verifier and examiner offers so many benefits from both a personal and a professional perspective. Being able to view things from an alternative outlook, witness and share best practice, and participate in and provide guidance, knowledge and expertise, are all priceless.”

Chantell Hodgson, Head of a Recognised External Quality Assessment Service for cellular pathology organisations



- ◆ We started hosting regular **webinar sessions on our Support Forum** in 2024 to support trainers and training officers in the laboratory. These are supporting experienced and new training officers to share ideas and solve problems together. Topics include reflective writing skills and leadership and management in laboratory services.
- ◆ Our collaboration with **NHS England and Health Education England** means that learners across England received significant financial support to complete IBMS qualifications. This included:
 - ◇ **£211,000** for the Certificate of Expert Practice
 - ◇ **£14,000** for the Higher Specialist Diploma (HSD) in Leadership and Management
 - ◇ **£363,000** for Histology Reporting
 - ◇ **£255,000** for Cytology, Dissection and Immunocytochemistry
 - ◇ **£123,000** for HSD in Scientific Disciplines.

WE PROGRESSED MEMBERS' CAREERS AND PROFESSIONAL DEVELOPMENT

- ◆ We recruited **new learning and digital roles at the IBMS** to better serve our members. For example, we recruited a **Head of Digital Education**, who created digital versions of the IBMS Registration Training Portfolio and developed training and resources for candidates, training officers and verifiers.
- ◆ Most of the **Specialist Portfolios were moved online** in 2024 to make them more accessible to members. Candidates can now submit all of their evidence on a single platform, examiners can review and assess submissions digitally, and training officers can review evidence before it is submitted and track it after.
- ◆ The number of examiners increased by **23%** between 2022 and 2025, bringing the total to **612**. This is helping us to assess more registration training and specialist qualifications for biomedical scientists.
- ◆ Since 2023, we have been hosting **regular webinars for members on the IBMS Support Hub** on our website. This includes topics such as: how to write a CV; equity, diversity and inclusion (EDI) in biomedical science; and biomedical scientist careers in the armed forces.

- ◆ We launched a campaign in 2025 to **promote IBMS qualifications and explain how they can help members to progress their careers**. The aim was to increase people's understanding of the different qualifications. This included creating three videos, which we shared on social media, in our newsletters and on our website. We have also developed the qualifications section on our new website, to make our qualifications easier to understand and access:

www.ibms.org/qualifications.html



It is important to keep our profession recognised as we play a major part in patient diagnoses. I also think it is important to continue to grow and develop trainee biomedical scientists, to future-proof our services and ensure we provide the best possible service that we can deliver.”

Lisa Cunningham, Quality Manager Blood Sciences (plus 24 years in Cellular Pathology previously), Jersey General Hospital

WE PROMOTED THE HIGHEST IBMS QUALIFICATIONS

- ◆ We developed new, and updated existing, **Advanced Specialist Diplomas (ASDs)**:
 - ◆ In 2023, we launched an updated version of the ASD in **Ophthalmic Pathology**. This is helping biomedical scientists to validate their expert knowledge and skills in dissecting and reporting selected ophthalmic pathology samples (tissues and fluids from the eye). They will also become a Fellow of the IBMS.
 - ◆ In the same year, we launched an ASD in **Bowel Screening Histopathology Reporting** and one in **Cervical Histopathology Reporting**. Biomedical scientists who take on these roles after qualifying will help to reduce waiting times for cancer diagnosis.
 - ◆ We also revised our ASD in **Histological Dissection**. These qualifications are aimed at senior members of our profession who have the ability and opportunity to take on some roles that are similar to those of medical consultants



- ◆ We launched a new **Diploma of Expert Practice** in **Ultrastructural Pathology** in 2025. Ultrastructural pathology provides a detailed examination of tissues at a microscopic level and can help diagnose certain cancers and rare genetic disorders.
- ◆ In 2023, we launched a new **Certificate of Expert Practice** (CEP) in **laboratory IT and clinical information**. This provides extra support for biomedical scientists taking on more information technology-based roles.



“

I joined the IBMS for the educational resources. I've done the Registration Portfolio, the Specialist Portfolio and the Certificate of Expert Practice. Without these opportunities, I wouldn't be at the point in my career that I am at today. As a training lead for my laboratory, I'm now supporting other biomedical scientists to do these qualifications.”

Chloe Aman, Advanced Biomedical Scientist in the Blood Transfusion department at Southampton General Hospital



THEME TWO:

WE PROMOTED THE PROFILE OF THE IBMS POST-PANDEMIC

We had great successes with our public and government engagement work in our last strategy. This significantly raised the profile of the IBMS and highlighted the vital role of the profession. During the course of the strategy, we worked with public affairs consultancy PLMR to grow this area of work.

Here are some of our achievements:

- ◆ We collaborated with other scientific bodies to lobby for changes in immigration policy, contributing to [a paper drafted by NHS Employers at the request of the Department of Health and Social Care](#). We worked with NHS England, the HCPC and the Department of Health and Social Care. It addressed the increased pay thresholds for international recruitment and changes to how occupations are considered for visas.
- ◆ We built stronger links with MPs, ministers and health leaders across the UK. This included with [MP Greg Smith](#), who raised awareness in parliament of the need for a sustainable supply of biomedical scientists into the NHS after he attended our January 2024 session in Parliament.
- ◆ We published guidance, white papers and workforce plans:
 - ◆ In 2022, we began publishing [practical professional guidance with a clear policy message](#). Our early work focused on supporting safe, consistent training and service delivery, including updating IBMS laboratory training guidance.
 - ◆ In 2023, we moved into a more strategic phase with the [IBMS Long Term Biomedical Scientist Workforce Plan](#). This set out actions to build, retain and develop the biomedical science workforce.
 - ◆ We then started publishing targeted white papers to show where [diagnostic services could benefit the healthcare system](#). We worked in partnership with Microsoft for Healthcare in 2023 to produce a white paper on digital pathology. Then, in 2024, we worked with AstraZeneca UK to publish a white paper on how the biomedical scientist workforce could help to create sustainable capacity for cancer testing.

- ◆ In 2024, we published two white papers, setting out [practical routes to improving access, consistency and modernisation within cervical screening services](#).
- ◆ In 2025, we partnered with Roche Diagnostics to publish the [Power of Testing](#), with support from the Royal College of Pathologists and the Association for Laboratory Medicine. It showed that the UK can build a more preventative, efficient and resilient healthcare system fit for the future by prioritising investment in in vitro diagnostics across the NHS. These are tests that can detect disease, conditions and infections.
- ◆ At the end of 2025, we strengthened the evidence base for transforming pathology services, by commissioning [Lord Patrick Carter](#) to lead an independent UK-wide review. This review of pathology services will provide a clear baseline for the workforce, meaning future decisions will be grounded in robust, comparable data. We are working in partnership with other healthcare professional bodies to engage pathology services and evaluate the findings.

- ◆ We responded to key policy reports and inquiries, reinforcing our voice of the biomedical science profession. This included:
 - calling for **more investment in diagnostics and community-based services** in our response to Lord Darzi's independent investigation into the NHS
 - calling for the **unique capabilities of the biomedical science community to be integrated into future pandemic preparedness plans** following the UK COVID-19 Inquiry's findings
 - highlighting the importance of **investing in innovative diagnostics, such as artificial intelligence-driven tools in laboratories and telehealth**, in our response to the UK government's 10-year Health Plan.



- ◆ We raised the profile of the profession at events, policy discussions and sector conferences. This included organising the **biennial IBMS Congress**. **IBMS Congress** events during the strategy period demonstrated their continued success, attracting **over 4,000 attendees** and strong exhibitor engagement. Overall attendance increased from **3,844 in 2023** to **4,037 in 2025**, with exhibition visitors rising by nearly **38%**. This highlights Congress's vital role in bringing the profession together, supporting professional development, and showcasing innovation across biomedical science.
- ◆ We advocated for **investment in the biomedical science workforce** to strengthen the diagnostics sector and ease pressures in the NHS. To meet growing demands, we called on the UK government to increase capacity in biomedical science, improve retention of staff, and unlock funding for training positions. Securing funding from the UK government is crucial to maintaining a robust talent pipeline and making sure patients receive earlier, more effective treatments.
- ◆ In 2025, we engaged with the UK government's health reform programmes, including the **10 Year Health Plan**. This included drafting and submitting formal responses to calls for evidence, developing policy briefings, and speaking with ministers, parliamentarians and officials. This helped to position biomedical science at the centre of diagnostics policy across the UK nations.





WE PROGRESSIONED THE NUMBERS AND DIVERSITY OF OUR MEMBERSHIP

- ◆ We introduced a **new pricing structure for members from low- and medium-income countries**. We changed from using the United Nations list of least developed countries to applying the discount to overseas members through the World Banking List. Now, the number of members who benefit from the 50% discount has increased from 46 to 138.
- ◆ We set up an **EDI Working Group** in 2022 to make sure we listen to a wide range of our members' voices. Creating an inclusive environment will help to bring new perspectives, opportunities, approaches and ideas to the profession. Since 2017, the IBMS has used the Science Council Diversity and Inclusion Progression Framework to track its progress on diversity and inclusion. In July 2025 the Science Council published our progress against this framework. The findings include:
 - ◆ We established strong governance and commitment from leadership on EDI. This includes our **EDI Working Group**, with two executive leads and a named trustee accountable for EDI. EDI is included on every Council agenda and is regularly discussed at board meetings.
 - ◆ Our events, marketing and communications all have EDI on the agenda. We include a range of **EDI topics in our membership magazine Biomedical Scientist** and in regular webinars and events.

WE SUPPORTED PEOPLE'S UNDERSTANDING OF THE PROFESSION BY DEMONSTRATING THE VALUE OF BIOMEDICAL SCIENCE

- ◆ The presence of biomedical scientists in the bowel cancer patient pathway benefits the NHS by an estimated £115 million to £571 million a year. That was one of the findings of an independent report, from economics consultancy Oxera, about the **impact of biomedical scientists on the bowel cancer patient pathway**. It demonstrates the need for wider recognition from government of the contribution of the biomedical scientist workforce.
- ◆ The British Journal of Biomedical Science (BJBS) achieved its highest-ever **Impact Factor of 4.6** in the 2025 Journal Citation Reports, placing it in **Quartile 1** and **fifth overall** in its subject category. This milestone reflects the journal's growing influence and its continued success in publishing high-quality, peer-reviewed research that supports and advances biomedical science in clinical practice.



Our strategy for 2026-2029

Our new strategy builds on the success of our last one and runs from 2026 to 2029.

The strategy is split into two parts with a series of aims. These are:

PART ONE: WE WILL EXTEND OUR EXPERIENCE AND EXPERTISE

◆ AIM 1

We will continue to support the biomedical science workforce by delivering a sustainable pipeline of future biomedical scientists who are HCPC-registered, and supporting those working in the field with relevant qualifications and training.

Currently, there are about 4600 people who are eligible to become biomedical scientists each year. But only around 1200 people a year become biomedical scientists. We want to make sure as many people as possible can take on this role so our laboratories have a sustainable workforce. We will do this by:

- ◆ encouraging greater recognition for trainers and trainees. If we can support more people to become dedicated trainers, we can grow the biomedical science workforce.



◆ AIM 2

We will progress our current members' careers by providing more relevant CPD, training and qualifications. We will also foster and support equality, diversity and inclusion in the workplace and champion our members' values and clear professional standards.

To do this, we will:

- ◆ make sure all of our members have access to relevant high-quality CPD that they can do at their own pace, including providing CPD on topics like wellbeing and EDI, which are newer components of the HCPC registration requirements for CPD; our focus is on building the skills that well-rounded healthcare professionals need to progress in their careers
- ◆ support members to develop leadership skills
- ◆ identify gaps in current qualifications so more biomedical scientists can progress in their careers and take on advanced roles.

◆ AIM 3

We will promote our highest qualifications by supporting consultant biomedical scientist roles where services and patients will benefit from their presence. We will widen the disciplines of these qualifications and increase the number of members accessing them.

Only around 200 biomedical scientists currently occupy consultant roles. To increase the number of biomedical scientists taking on consultant roles, we will:

- ◆ raise awareness of the benefits that consultant biomedical scientist roles in healthcare offer; we will continue to talk about the importance of these roles and how they add value to services
- ◆ promote and support greater uptake of advanced qualifications
- ◆ continue to develop new qualifications where a clear need is identified.



PART TWO: WE WILL BUILD AND DEVELOP OUR FUTURE

◆ AIM 1

We will promote our profile and that of our members, to further develop a policy and engagement capability at government and international level.

We will do this by:

- ◆ continuing with our public and government engagement work to further raise the profile of the IBMS and demonstrate the value of the profession
- ◆ continuing to publish reports and white papers and develop guidance aimed at the UK government
- ◆ celebrating our membership and the profession through public engagement and membership events.

◆ AIM 2

We will retain, expand and diversify IBMS membership across the UK and internationally.

We will do this by:

- ◆ developing tailored benefits that meet the evolving needs of current and future members
- ◆ actively promoting IBMS membership to registered biomedical and clinical scientists
- ◆ setting up an international faculty to share experiences, gain insights from across the globe and provide advocacy to international bodies and governments
- ◆ developing a CPD offer that is relevant to members, wherever they work.

◆ AIM 3

We will increase understanding of the benefit and impact that the profession and biomedical science delivers to society by promoting our members' values and how these are applied in practice.

We will do this by:

- ◆ continuing to undertake peer-reviewed and evidence-based research to promote the profession
- ◆ identifying opportunities where the IBMS can support the profession
- ◆ continuing to develop areas of work that are important to members' values, including sustainability, well being and EDI.

◆ AIM 4

Ensure that the IBMS remains robust and sustainable to support members in the years to come to encourage continued membership throughout their careers.

We will do this by:

- ◆ making sure the IBMS can continue to deliver high-profile educational events and services needed by members
- ◆ ensuring the IBMS attracts and works with the best talent in terms of staff, volunteers and experts
- ◆ making sure the IBMS diversifies its income in line with its aims and objectives
- ◆ ensuring the organisation's infrastructure (e.g. member-facing systems, back-office systems and staffing) is robust, and up to date.



I really love being a member of the IBMS. I joined 30 years ago because I wanted to learn more about the background to my profession, how it functioned and what was available to me. I love the way the IBMS is much more visible now. They make sure our voices are heard with other professional bodies, the public and government.”

Victoria Bradley, a Reader in Biomedical Science
Clinical Practice Education at Cardiff
Metropolitan University and
an IBMS Council member
for Wales

**Institute of Biomedical
Science**
12 Coldbath Square
London
EC1R 5HL
United Kingdom

Benefits of membership

Being a member of the IBMS has a number of benefits, including:

- helping you to progress your career through accredited qualifications and training
- giving you access to professional standards and support
- enhancing your knowledge and skills through our continuing professional development scheme
- accessing professional and scientific publications
- free legal advice on workplace issues and other personal matters, such as being involved in an accident or buying a property
- discounts on cinema tickets, holidays and health clubs.

To find out more about being a member of the IBMS, call 020 7713 0214 or email mail@ibms.org

Call: +44 (0)20 7713 0214

Email: mail@ibms.org

Visit our website: www.ibms.org

Join us on Facebook: [/Biomedicalseience](https://www.facebook.com/Biomedicalseience)

LinkedIn: [Institute of Biomedical Science](https://www.linkedin.com/in/InstituteofBiomedicalScience)

Follow us on Instagram: [@IBMScience](https://www.instagram.com/IBMScience)

Watch us on YouTube:

[InstituteofBiomedicalScience](https://www.youtube.com/user/InstituteofBiomedicalScience)